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Introduction
Appreciation of the relative benefits of noninvasive venti-
lation (NIV), which is the provision of mechanical res-
piratory assistance without the need for the insertion of
an endotracheal airway for a patient, in the manage-
ment of acute respiratory failure appears to be increas-
ing not only in intensive care units (ICUs) but also in
emergency departments1–4 and general wards.1 Given
that a number of well-designed randomized controlled
trials have demonstrated the relative efficacy of NIV as
regards averting the need for intubation in ventilatory-
support patients, NIV is now being considered more
as the respiratory support of choice for acute respira-
tory failure.1–4 As patient intubation can be avoided
with NIV, morbidity, mortality and length of hospital
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stay are consequently reduced.1,2 NIV can also be
applied to reduce the need for mechanical ventilation in
selected patients.1,2 For some patients, however, appli-
cation of NIV may lead to clinicians missing the optimal
time window for intubation, and thus result in a poorer
patient outcome than would have been the case if appro-
priately timed intubation had been conducted.1,2
Therefore, the correct identification of such patients
would constitute a desirable goal. The proportion of
such patients amongst the total pool of respiratory-
assist patients varies from study to study.1,2 Further, the
response to NIV treatment cannot necessarily be pre-
dicted by the relative severity of the existing underlying
lung disease as indicated by forced expiratory volume
in the first second of forced exhalation (FEV1), arterial
blood-gas levels, or by arterial blood-gas and blood
parameter values (PCO2, pH, etc.) obtained prior to
commencing NIV.1,2 Clearly then, clinicians have, for
some time, been frustrated by their inability to accu-
rately predict the continuum of NIV.
The rapid shallow breathing index (RSBI) was intro-
duced in 1991 by Yang and Tobin2 and was found to be
an accurate index for predicting ventilator weaning suc-
cess. In contrast, however, to the best of our knowledge,
few, if any, previous studies have attempted to evaluate
the relative feasibility of using the RSBI to predict the
outcome of NIV therapy for individuals suffering from
acute respiratory failure. To evaluate the relative feasibil-
ity of using RSBI and other respiratory indices to accu-
rately predict the outcome of NIV treatment of acute
respiratory failure, we conducted a prospective study
in the ICU of a teaching hospital in Chia-Yi, Taiwan.
Methods
Patients
We recruited study participants from a group of patients
with acute respiratory failure who had been admitted
to the adult ICU of our institution between October
1, 2004 and September 30, 2005 inclusively and who
had received mechanical ventilation subsequent to their
admission. If the patients met the following criteria,
they were initially treated with NIV: (1) stable hemody-
namic condition; (2) no need for endotracheal intubation
to handle secretion; (3) no upper airway obstruction;
(4) no bulbar dysfunction; (5) no life-threatening
arrhythmias; and (6) no massive upper gastrointestinal
bleeding. Initially, all the patients received NIV featur-
ing a bi-level positive airway pressure (BiPAP) mode
together with conventional treatment modalities, in-
cluding oxygen therapy, bronchodilators, corticosteroids
and antibiotics, as needed. Conventional mechanical
ventilation was applied if the above medication and
treatment strategy were deemed to have failed, and/or
if patients exhibited unfavorable arterial blood-gas or
blood parameter levels (PaO2 < 55 mmHg with oxy-
gen supplementation or blood pH < 7.30) or clinical
signs of respiratory distress such as tachypnea, use of
accessory muscles for respiration and/or paradoxical
respiratory movement. Patients with unstable hemo-
dynamic status (defined as the need for administration
of inotropic agents to maintain systolic blood pres-
sure > 90 mmHg), life-threatening arrhythmias, facial
deformity or tracheostomy were excluded, as were
those who received intubation for the removal of exces-
sive respiratory secretions. This study was approved by
the Research Committee of the hospital in which the
study was conducted.
Data collection
The RSBI was measured using a hand-held spirometer
(Boehringer Laboratory, Wynnewood, PA, USA) while
the patient breathed through a mouthpiece, with a nasal
clip on the nose to avoid air leakage. According to the
suggestion of Yang and Tobin,2 study patients were
asked to breathe through the Wright respirometer for
a period of 1 minute. Patient respiratory rate (RR) and
tidal volume (VT) were measured by the Wright
respirometer, after which the RR value was divided by
the VT value to calculate the RSBI (RR/VT). Mea-
surement of the maximal inspiratory pressure (PImax)
and the maximal expiratory pressure (PEmax) were
conducted using an inspiratory force meter (Ferraris
Medical Ltd., Hertford, England) using the same pro-
cedures as those used for measuring the RSBI. Because
all patients in the study group were suffering from
acute respiratory failure, it was not feasible to occlude
the airway to obtain the measurements. Therefore,
patients were asked to exhale and inhale vigorously
prior to the determination of PImax and PEmax. Whilst
it could be construed that this option might introduce
some level of variability into the measurement accuracy
for PImax and PEmax, given that the procedure adopted
for such parameter assessment was the same for all
patients, the variability was deemed unlikely to intro-
duce remarkable bias to the study results. As the Acute
Physiology and Chronic Health Evaluation (APACHE)
II1 scores were recorded for the study patients at the
time of their admission to the ICU, the PImax, PEmax,
RR, VT, and RSBI measurements were repeated using
the same hand-held spirometer and inspiratory force
meter, prior to NIV application (denoted by a sub-
scripted number 0), and also 30 and 60 minutes sub-
sequent to NIV application (denoted by, respectively,
a subscripted 30 and subscripted 60).
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NIV
All the physicians, respiratory therapists, and nurses in
the ICU who were involved with the study had been
well trained on the application of NIV techniques
prior to study commencement. Portable BiPAP venti-
lators (Respironics, Murrysville, PA, USA) were used
in the spontaneous mode, and the interface was adapted
as a full-face mask. For the management of NIV, we
adopted the approach applied, in 2000, by Antón et al
as part of an earlier analogous study.5 In short, the
inspiratory positive airway pressure (IPAP) level was
initially set at 10 cmH2O and then gradually increased
until the respiratory rate fell to 25 breaths per minute
without excessive usage of any accessory respiratory
muscles. In order to facilitate comparisons between all
patients, the expiratory positive airway pressure (EPAP)
value was set at 4 cmH2O without any back-up rate
for all participants. The duration of the NIV session
performed for our study participants was similar to
that used for other studies and depended on the
patient’s tolerance to ventilation. We considered that
treatment with NIV was successful if endotracheal intu-
bation was avoided and if the patients were able to be
subsequently discharged from hospital.
Criteria for termination of NIV
If any 1 of the following situations were detected by
the physician or the respiratory therapist in charge,
the NIV procedure was terminated and endotracheal
intubation with invasive ventilation was immediately
commenced: (1) decompensated respiratory acidosis
featuring CO2 retention and blood pH < 7.30; (2)
oxygen desaturation with an SpO2 value < 90% in spite
of high oxygen supplementation (up to 15 L/min);
(3) inability to tolerate the NIV mask due to discomfort
or pain; (4) need for endotracheal intubation to manage
secretions and/or to protect the airway; or (5) hemo-
dynamic instability.
Statistical analysis
Results are expressed herein as mean ± standard devia-
tion, or mean (95% confidence interval). Differences
and interval changes for serial respiratory indices (RR,
VT, PImax, PEmax, RSBI) between the success and
failure groups for continuous NIV application were
evaluated using Student’s t test, whilst differences in
categorical data were assessed using the χ2 test. Interval
changes with respect to indices within each study group
were evaluated using paired t tests. The independent
effects of these variables on outcome were evaluated
using multivariate logistic regression analyses. All
variables featuring a p value < 0.10 for the univariate
analyses were included as independent variables in the
initial multivariate regression model, and the final
model was constructed following exclusion of the vari-
ables that featured a p value > 0.25. The area under the
receiver operating characteristic curve (AUROC) for
each serial respiratory index was also calculated to evalu-
ate the capacity to predict the success of NIV treatment
or otherwise. The sensitivity, specificity, positive predic-
tive value, and negative predictive value were not
reported in order to avoid dependence on a threshold
value.2
Results
All 86 patients who satisfied the inclusion criteria agreed
to participate in this study, of whom 55 (64%) were
defined as being successful cases (the success group),
and 31 (36%) as cases that failed NIV treatment (the
failure group). The underlying diseases included pneu-
monia (16 patients), chronic obstructive pulmonary
disease (COPD) with exacerbation (15 patients), acute
cardiogenic pulmonary edema (14 patients), post-
extubation stridor (11 patients), and sepsis (11 patients)
(Table 1). Among the 5 most common underlying
diseases for this group of 86 patients, post-extubation
stridor had the highest rate of successful NIV treatment
(91%), followed by sepsis (82%) and acute cardio-
genic pulmonary edema (79%), with pneumonia fea-
turing the lowest rate of NIV treatment success
(38%).
Of the parameters measured prior to NIV treat-
ment, only the APACHE II scores were significantly
lower for the success group than for the failure group
(p = 0.001), with the AUROC value here being 0.72
(Table 2). Of the serial respiratory measurements taken,
PImax30 (p=0.05), RR30 (p=0.01), and RR60 (p=0.03)
were significantly lower for the success group than 
for the failure group, and the corresponding AUROC
values were, respectively, 0.64, 0.65, and 0.61. When
making intergroup comparison, none of the serial RSBI
measurement values (taken prior to and at 30 and 
60 minutes subsequent to NIV treatment) differed
significantly.
Amongst the interval changes for respiratory indices,
PImax0–60, RR0–30, RR0–60, RSBI0–30, and RSBI0–60 for
the success group, and PEmax0–60, VT0–30, VT0–60, and
RSBI0–60 for the failure group proved to differ statis-
tically significantly (Table 3). When comparing the 2
study groups, only the differences in PEmax0–60
(p = 0.04) and RR0–30 (p = 0.01) attained what we
deemed to be a statistically significant level, with the
AUROC values for the success and failure groups
being, respectively, 0.61 and 0.66 (Table 3). Further,
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interval changes as regards RSBI did not differ statis-
tically significantly between the 2 groups.
Six respiratory indices (APACHE II, PImax30, RR30,
RR60, PEmax0–60, RR0–30) were found to be significant
in the univariate logistic regression analyses; thus, all
were included in the initial multivariate logistic regres-
sion model (Table 4). However, RR30 was excluded due
to its significant correlation to RR60 (Pearson’s corre-
lation coefficient = 0.86; p = 0.001). Further stepwise
forward and backward selection excluded PImax30, so
the final model included APACHE II, RR60, PEmax0–60,
and RR0–30 (Table 4).
When separate analyses were performed on data
relating to underlying diseases afflicting more than 10
study patients (including pneumonia, COPD, acute
cardiogenic pulmonary edema, sepsis, extubation stri-
dor), none of the indices appeared to be a significant
independent predictor of treatment outcome for the
study participants (data not shown), this being most
likely due to the influence of a rather small sample size.
Table 2. Differences in demographic and respiratory indices between the success and failure groups*
Index
NIV treatment
p at difference AUROC
Success group (n = 55) Failure group (n = 31)
Male/Female ratio 1.04 0.94 0.82
Age (yr) 70.8 ± 14.1 73.4 ± 13.9 0.40 0.56
APACHE II score 16.2 ± 6.5 20.8 ± 4.9 0.001† 0.72
PImax0 (cmH2O) −23.0 ± 14.7 −20.3 ± 16.2 0.43 0.57
PImax30 (cmH2O) −25.2 ± 13.0 −19.7 ± 12.2 0.05† 0.64
PImax60 (cmH2O) −26.8 ± 15.3 −21.3 ± 12.8 0.11 0.61
PEmax0 (cmH2O) 23.4 ± 13.8 20.2 ± 10.8 0.26 0.55
PEmax30 (cmH2O) 23.4 ± 12.0 22.2 ± 10.4 0.65 0.51
PEmax60 (cmH2O) 24.2 ± 12.6 26.9 ± 13.4 0.39 0.55
RR0 (breaths/min) 27.8 ± 6.9 29.6 ± 7.9 0.28 0.55
RR30 (breaths/min) 24.9 ± 5.6 28.8 ± 7.9 0.01† 0.65
RR60 (breaths/min) 25.2 ± 5.9 28.6 ± 7.8 0.03† 0.61
VT0 (mL) 350.5 ± 154.4 316.1 ± 137.9 0.30 0.56
VT30 (mL) 380.4 ± 176.5 367.3 ± 175.6 0.74 0.52
VT60 (mL) 378.6 ± 167.5 406.2 ± 158.1 0.49 0.56
RSBI0 (breaths/min/mL) 100.2 ± 58.2 113.7 ± 64.4 0.32 0.58
RSBI30 (breaths/min/mL) 84.4 ± 50.0 101.8 ± 71.7 0.19 0.57
RSBI60 (breaths/min/mL) 80.8 ± 41.4 82.1 ± 40.8 0.90 0.51
*Data are presented as mean ± standard deviation; †p < 0.05, NIV treatment success vs. failure. NIV = noninvasive ventilation; AUROC = area under the
receiver operating characteristic curve; APACHE = Acute Physiology and Chronic Health Evaluation; PImax = maximum inspiratory pressure; PEmax = maximum
expiratory pressure; RR = respiratory rate; VT = tidal volume; RSBI = rapid shallow breathing index.
Table 1. Distribution of underlying diseases amongst study participants
Underlying disease
NIV treatment
Success rate, %
Success group, n (%) Failure group, n (%) Total, n
Pneumonia* 6 (11) 10 (32) 16 38
COPD 9 (16) 6 (19) 15 60
Acute cardiogenic pulmonary edema 11 (20) 3 (10) 14 79
Sepsis 9 (16) 2 (6) 11 82
Extubation stridor 10 (18) 1 (3) 11 91
UTI 4 (7) 1 (3) 5 80
Malignancy 1 (2) 2 (6) 3 33
CNS diseases 1 (2) 2 (6) 3 33
Others 4 (7) 4 (13) 8 50
Total 55 (100) 31 (100) 86 64
*Defined as leukocytosis, purulent sputum, and a new infiltration patch on chest X-ray. NIV = noninvasive ventilation; COPD = chronic obstructive pulmonary
disease with acute exacerbation; UTI = urinary tract infection; CNS = central nervous system.
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Discussion
The success rate for NIV treatment in our study was
64%, a figure that is similar to results from a number of
previous studies, although it was apparent that there
did exist a number of interstudy differences as regards
underlying diseases amongst study participants.3 Most
of the major underlying diseases determined in our
study, including pneumonia, COPD, acute cardiogenic
pulmonary edema, and post-extubation stridor, were
indicative for NIV application, as was also revealed by
the authors of a number of earlier studies.3,4,6–9
Many previous studies have attempted to assess the
relative effectiveness of NIV treatment, but as best as
we are aware, few have attempted to perform a com-
prehensive evaluation of the use of respiratory indices
such as PImax, PEmax, RR, and VT for the purposes
of predicting NIV treatment outcome. Of the baseline
respiratory indices examined prior to the application
of NIV, we found that only the APACHE II score at
presentation, which constitutes an index of the relative
severity of patient illness at the time of assessment,
differed significantly between the 2 groups, with the
APACHE II values being greater for the failure
group, which featured AUROC values up to a figure
of 0.72. A number of previous studies relating to the
application of NIV for acute exacerbations of COPD
had similar observations.10–12 In contrast to such an
outcome, patient gender and age did not affect the
results of NIV treatment.
Subsequent to the initiation of NIV treatment, we
found that only patient RR was a significant predictor of
treatment success for within- and between-group analy-
ses. Specifically, RR30 and RR60 differed significantly
between the 2 groups. From a similar previous study
reported in 2003, Girault et al3 observed significant
Table 3. Interval improvement in respiratory indices prior to, and at 30 and 60 minutes subsequent to noninvasive ventilation (NIV)
treatment*
NIV treatment
p at difference AUROC
Success group Failure group
PImax0–30 (cmH2O) −2.8 (−5.5 ∼ 0.0) 0.6 (−5.0 ∼ 6.2) 0.22 0.60
PImax30–60 (cmH2O) −1.5 (3.8 ∼ 0.9) −0.7 (−3.0 ∼ 1.6) 0.68 0.54
PImax0–60 (cmH2O) −4.0 (−7.0 ∼ −1.0)† −2.6 (−5.9 ∼ 0.6) 0.57 0.55
PEmax0–30 (cmH2O) 0.6 (−1.8 ∼ 3.1) 2.1 (−0.7 ∼ 4.8) 0.44 0.55
PEmax30–60 (cmH2O) 0.5 (−1.4 ∼ 2.4) 3.4 (−0.3 ∼ 7.0) 0.13 0.58
PEmax0–60 (cmH2O) 1.1 (−1.9 ∼ 4.2) 6.0 (2.7 ∼ 9.4)† 0.04‡ 0.61
RR0–30 (breaths/min) −2.9 (−4.1 ∼ −1.8)† −0.8 (−2.0 ∼ 0.4) 0.01‡ 0.66
RR30–60 (breaths/min) 0.1 (−0.8 ∼ 1.0) −0.2 (−2.0 ∼ 1.5) 0.68 0.52
RR0–60 (breaths/min) −2.7 (−4.2 ∼ −1.1)† −1.0 (−3.0 ∼ 0.9) 0.20 0.57
VT0–30 (mL) 31.1 (−6.3 ∼ 68.6) 51.3 (18.6 ∼ 83.9)† 0.46 0.56
VT30–60 (mL) 0.0 (−33.4 ∼ 33.4) 3.9 (−27.7 ∼ 35.4) 0.88 0.49
VT0–60 (mL) 23.5 (−11.9 ∼ 58.8) 71.0 (33.9 ∼ 108.2)† 0.10 0.65
RSBI0–30 (breaths/min/mL) −16.6 (−28.0 ∼ −5.2)† −12.0 (−26.9 ∼ 3.0) 0.61 0.48
RSBI30–60 (breaths/min/mL) −4.3 (−11.2 ∼ 2.5) −3.2 (−11.7 ∼ 5.3) 0.84 0.53
RSBI0–60 (breaths/min/mL) −16.8 (−27.3 ∼ −6.4)† −20.9 (−32.4 ∼ −9.4)† 0.63 0.53
*Data are presented as mean (95% confidence interval); †p < 0.05 within the NIV treatment success and failure groups; ‡p < 0.05 between the NIV treatment
success and failure groups. AUROC = area under the receiver operating characteristic curve.
Table 4. Odds ratios (OR) and associated 95% confidence intervals (CI) for the success group as obtained from logistic regression analyses
Index
Initial model* Final model†
OR‡ 95% CI p OR‡ 95% CI p
APACHE II score 0.024 0.001–0.560 0.03§ 0.024 0.001–0.546 0.02§
PImax30 (cmH2O) 0.239 0.005–7.594 0.44 NI NI NI
RR60 (breaths/min) 0.007 0.000–8.511 0.18 0.014 0.000–0.632 0.04§
PEmax0–60 (cmH2O) 0.013 0.000–0.662 0.04§ 0.017 0.000–0.703 0.05§
RR0–30 (breaths/min) 0.031 0.001–1.090 0.07 0.023 0.000–0.716 0.05§
*Included all 6 indices studied; †obtained through stepwise model construction and included only significant independent predictors; ‡odds ratio of NIV treatment
success associated with each unit increase in the index; §p < 0.05. NI = not included in the final model.
differences 2 hours following NIV treatment com-
mencement, and beyond 2 hours, whereas in 2001,
Plant et al13 observed significant differences 4 hours
subsequent to treatment commencement. In our study,
interval comparisons further demonstrated that the
response to NIV treatment that occurred within the
initial 30 minutes of NIV treatment (RR0–30) was also
significant within the success group. As such, this param-
eter still proved to be a significant predictor of NIV
treatment success after having adjusted for APACHE II
scores and other indices as presented in the final multi-
variate regression model.
Although RSBI would appear to be a reasonably
good predictor for the weaning of a patient from inva-
sive intubation,14 we did not find this parameter to be
a significant predictor of successful NIV treatment for
either the serial or the interval changes. The fact that
improvements to RSBI following NIV treatment were
similar for the 2 study groups may have been due to the
simultaneous interval improvements that arose within
each group following NIV treatment, improvements
which could be related to the “counteraction” between
the improvement in RR0–30 for the success group and
the improvement in VT0–30 for the failure group. The
improvement in RR following NIV treatment was
independent of the treatment-elicited increase in VT
(Table 3), and such an outcome could probably be
explained by the NIV-elicited reduction of the extent
of acidosis present prior to treatment.
The relative success of NIV treatment may be
related to its impact on some of the underlying diseases,
or simply to NIV application per se, or both. As regards
the data relating to early responses, PEmax and VT
improved in the failure group following NIV treat-
ment, but this was not the case for the success group.
Such a result could be related to the relative progres-
sion of the pre-existing underlying diseases during
NIV treatment regardless of the relative improvement
in respiratory load by such treatment. Clearly, further
longer-term observations of these variables as part of
a future study are warranted.
Among the 5 most common underlying diseases
in our study patients, post-extubation stridor had the
highest rate of treatment success (91%), and pneumonia
the lowest (38%). In general, study participants with
post-extubation stridor featured improved/improving
clinical conditions prior to extubation, this being the
principal reason for which extubation was performed.
Therefore, even though such individuals suffered from
stridor following extubation, their general condition was
relatively good, and so it is not surprising that they
featured a greater success rate with NIV. On the other
hand, study participants with pneumonia exhibited 
a downhill progression of their general condition
which led to acute respiratory failure. Thus, the respi-
ratory system was both the main and the direct target
of the disease; consequently, these individuals’ respi-
ratory system was more vulnerable compared to that
of non-pneumonia patients, and thus the former became
less responsive to BiPAP therapy. Individuals featuring
COPD with acute exacerbations are, generally, indi-
viduals who would appear to benefit the most from
BiPAP therapy, but this group of patients in our study
did not demonstrate a greater rate of success with NIV
treatment than other groups. Such a result might be
attributable to the fact that many of the COPD-afflicted
study participants were of older age, and a substantial
number of them were bedridden. Therefore, many of
these individuals had bronchospasms and problems
related to secretion from the respiratory tract, which
might lead to a relatively low success rate.
From our study, the highest AUROC value from
amongst all the respiratory indices was observed for the
APACHE II scores (0.72). Although the AUROC
values for some of the respiratory indices did exhibit
significant differences during comparison between the
success and failure groups, no single index alone was
able to be applied to explain the relative success of
NIV treatment outcome. Some previous studies have
shown that a good level of patient consciousness and
a lower APACHE II score at the outset of NIV treat-
ment, and the extent of the initial improvement in pH,
PaCO2, and RR are significant predictors of NIV treat-
ment outcome.15,16 In 2000, Antón et al5 reported a
multivariate predictive model that featured an adequate
power of discrimination that could correctly classify
more than 95% of the patients in a subsequent sample
of new patients. Some of these above-mentioned stud-
ies combined both clinical and laboratory data, the
combination of which may, on occasion, be too complex
for clinical application. Moreover, for application in
the emergency department of a hospital, as well as for
general wards, clinical parameters relating to initial
patient responses to NIV treatment should be explored
by researchers as a part of further studies. This would
be appropriate since it may not always be possible at
the outset of NIV treatment for clinicians to predict
which individuals will benefit from treatment.
In conclusion, we evaluated the application of var-
ious respiratory indices in the prediction of NIV
treatment outcome in patients with acute respiratory
failure. None of the respiratory indices addressed prior
to the commencement of NIV treatment appeared to
be predictive of treatment outcome, although indi-
viduals who had a lower APACHE II score initially were
more likely to be associated with a poorer prognosis
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following treatment. Subsequent to the commence-
ment of NIV treatment, whilst we noted that RSBI was
not a significant predictor of successful NIV application,
improvements in RR, especially those arising during
the first 30 minutes subsequent to the application of
NIV treatment, were associated with a better patient
outcome.
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